Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

被引：1

作者：

Moreau, Philippe ^{[1
]}

Kumar, Shaji ^{[2
]}

Boccia, Ralph ^{[3
]}

Iida, Shinsuke ^{[4
]}

Goldschmidt, Hartmut ^{[5
]}

Cocks, Kim ^{[6
]}

Zahlten-Kumeli, Anita ^{[7
]}

Yucel, Emre ^{[7
]}

Panjabi, Sumeet ^{[7
]}

Dimopoulos, Meletios ^{[8
]}

机构：

[1] Univ Hosp Hotel Dieu, Nantes, France

[2] Mayo Clin, Rochester, MN USA

[3] Ctr Canc & Blood Disorders, Bethesda, MD USA

[4] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan

[5] Univ Hosp Heidelberg, Heidelberg, Germany

[6] KCStats Consultancy, Leeds, W Yorkshire, England

[7] Amgen Inc, Thousand Oaks, CA 91320 USA

[8] Univ Athens, Sch Med, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷

关键词：

multiple myeloma; carfilzomib; once-weekly; patient-reported outcomes; quality of life;

D O I：

10.1016/j.clml.2018.07.130

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-138

引用

页码：S240 / S240

页数：1

共 50 条

[31] Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study
Auner, Holger W.
Gavriatopoulou, Maria
Delimpasi, Sosana
Simonova, Maryana
Spicka, Ivan
Pour, Ludek
Dimopoulos, Meletios A.
Kryachok, Irina
Pylypenko, Halyna
Leleu, Xavier
Doronin, Vadim A.
Usenko, Ganna
Hajek, Roman
Benjamin, Reuben
Dolai, Tuphan Kanti
Sinha, Dinesh Kumar
Venner, Christopher P.
Garg, Mamta
Stevens, Don A.
Quach, Hang
Jagannath, Sundar
Moreau, Philippe
Levy, Moshe Y.
Badros, Ashraf Z.
Anderson, Larry D., Jr.
Bahlis, Nizar J.
Facon, Thierry
Mateos, Maria
Cavo, Michele
Joshi, Anita A.
Chai, Yi
Arazy, Melina
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Richardson, Paul G.
Grosicki, Sebastian
BLOOD, 2020, 136
[32] Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
Biran, Noa
Siegel, David Samuel DiCapua
Berdeja, Jesus G.
Raje, Noopur S.
Cornell, Robert F.
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy
Landgren, Carl Ola
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study
Mateos, Maria
Gavriatopoulou, Maria
Facon, Thierry
Auner, Holger W.
Leleu, Xavier
Hajek, Roman
Dimopoulos, Meletios A.
Delimpasi, Sosana
Simonova, Maryana
Spicka, Ivan
Pour, Ludek
Kryachok, Irina
Pylypenko, Halyna
Doronin, Vadim A.
Usenko, Ganna
Benjamin, Reuben
Dolai, Tuphan Kanti
Sinha, Dinesh Kumar
Venner, Christopher P.
Garg, Mamta
Stevens, Don A.
Quach, Hang
Jagannath, Sundar
Moreau, Philippe
Levy, Moshe
Badros, Ashraf Z.
Anderson, Larry D., Jr.
Bahlis, Nizar J.
Cavo, Michele
Chai, Yi
Arazy, Melina
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Richardson, Paul G.
Grosicki, Sebastian
BLOOD, 2020, 136
[34] Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
Lu, Jin
Geng, Liangquan
Chen, Lijuan
Liu, Peng
Zhong, Yuping
Liu, Zhuogang
Xia, Zhongjun
Mi, Jianqing
Li, Chunrui
Zhang, Xi
He, Yanjuan
Wei, Yongqiang
Fang, Baijun
Li, Fei
Cai, Zhen
Wang, Yafei
Huang, Dongping
Liu, Hong
Hou, Ming
Fu, Rong
Du, Xin
Fang, Xiaosheng
Zeng, Qingshu
Gao, Wen
Wang, Wei
Chang, Chunkang
Ouyang, Guifang
Liu, Jing
Weng, Jianyu
Huang, Xiaobing
Yu, Yang
Guo, Zhi
Zhao, Jun
Hou, Jian
BLOOD, 2024, 144 : 4748 - 4749
[35] Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts):A subgroup analysis from the phase 3 ARROW study.
Mateos, Maria-Victoria
Ludwig, Heinz
Kumar, Shaji
Rosenbaum, Cara Ann
Huang, Mei
Goldrick, Amanda
Blaedel, Julie
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] PATIENT-REPORTED OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE OVERALL AND JAPANESE POPULATIONS FROM ELOQUENT
McKendrick, J.
Zyczynski, T.
Kudlac, A.
Davis, C.
Cella, D.
VALUE IN HEALTH, 2016, 19 (07) : A891 - A892
[37] Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM).
Lonial, Sagar
Baz, Rachid C.
Wang, Michael
Talpaz, Moshe
Liu, Guohui
Berg, Deborah
Gupta, Neeraj
Di Bacco, Alessandra
Hui, Ai-Min
Richardson, Paul Gerard Guy
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[38] Efficacy and Safety of Once-Weekly Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Secondary Analysis from the CHAMPION-1 Study by Prior Lines of Therapy
Berdeja, Jesus
Rifkin, Robert
Lyons, Roger
Cartmell, Alan
Coleman, Morton
Yang, Hui
Zahlten-Kumeli, Anita
Iskander, Karim
Berenson, James
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E58 - E59
[39] Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
Berenson, James R.
Cartmell, Alan
Bessudo, Alberto
Lyons, Roger M.
Harb, Wael A.
Tzachanis, Dimitrios
Coleman, Morton
Boccia, Ralph V.
Rifkin, Robert M.
Patel, Priti
Dixon, Sandra
Berdeja, Jesus G.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM)
Hungria, Vania
Robak, Pawel
Hus, Marek
Fu, Chengcheng
Zherebtsova, Vera
Ward, Christopher
De Almeida, Ana Carolina
Ho, P. Joy
Hajek, Roman
Cerchione, Claudio
Pirooz, Nicholas
McKeown, Astrid
Baig, Hena
Eccersley, Lydia
Pompilus, Farrah
McNamara, Simon
Lin, Chee Paul
Roy-Ghanta, Sumita
Opalinska, Joanna
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →